<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546533</url>
  </required_header>
  <id_info>
    <org_study_id>0881A-101101</org_study_id>
    <nct_id>NCT00546533</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Efficacy and Safety of Etanercept</brief_title>
  <official_title>Open-Label Evaluation Of The Efficacy And Safety Of Etanercept In Patients With Active Rheumatoid Arthritis (RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      To assess the efficacy of etanercept 25 mg administered subcutaneously twice-weekly for 12
      weeks in patients with active RA for whom classical antirheumatic therapy is insufficient or
      inappropriate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the clinical efficacy of etanercept 25 mg administered twice-weekly for 12 weeks in patients with active RA for whom classical antirheumatic therapy is insufficient or inappropriate.</measure>
  </primary_outcome>
  <enrollment>40</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A negative serum or urine pregnancy test at screening and a medically acceptable form
             of contraception starting at screening and continuing throughout the study is required
             for all females of childbearing potential (defined as an oral, injectable, or
             implantable contraceptive, intrauterine device, or barrier method combined with a
             spermicide).

          -  Failed therapy with at least one DMARD (DMARD failure is defined as a discontinuation
             because of lack of clinical efficacy).

          -  Meet the 1987 American Rheumatism Association (ARA) revised criteria for rheumatoid
             arthritis.

        Exclusion Criteria:

          -  Uncooperative patients with a history of poor compliance.

          -  Known hypersensitivity to etanercept or any of its components.

          -  Known significant concurrent medical disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2007</study_first_submitted>
  <study_first_submitted_qc>October 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2007</study_first_posted>
  <last_update_submitted>October 18, 2007</last_update_submitted>
  <last_update_submitted_qc>October 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

